LONDON — Huntsworth has acquired Nucleus Global, one of the world’s largest specialist medical communications agencies, for an undisclosed sum.

It’s the group’s second healthcare acquisition since it was bought by private equity firm Clayton, Dubilier & Rice in March this year – it bought pharmaceutical communications and training firm Cormis in June – and underlines the group’s commitment to strengthening its healthcare offer.

Nucleus Global joins MediStrava, the Evoke Group – which includes Evoke Kyne, after Huntsworth bought David Kyne’s eponymous healthcare communications agency Kyne in 2019 – and The Creative Engagement Group in Huntsworth’s healthcare portfolio.

In its statement, the group said this latest acquisition means it can now provide pharmaceutical and biotechnology companies with strategic counsel, medical affairs, market access, stakeholder engagement and marketing services across all therapeutic areas and the entire drug development lifecycle.

Nucleus was founded in 1986 and has more than 800 employees in 14 offices. Huntsworth CEO Paul Taaffe said: “The addition of Nucleus Global to Huntsworth creates one of the largest high science teams in the world to meet the increasingly complex needs of next generation prescription drug development. Together, Nucleus Global, and Huntsworth are one of the most powerful combinations in healthcare communications.”

Stephen Cameron, Nucleus Global’s founder and chair (pictured), will join the Huntsworth board and continues to lead the firm. He said: “We are excited to combine our expertise with the breadth of solutions across Huntsworth to deliver even more value to our clients, and our teams, which will help them capitalise on their opportunities to provide patients with the most effective healthcare solutions.”

As well as its growing healthcare business, Huntsworth has the Constellation Communications group, whose agencies include Grayling, Red Consultancy and Citigate Dewe Rogerson.